48 results about "CEA Antibody" patented technology

A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry.

The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16^INK4A antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

The invention discloses a CEA TRFIA (time-resolved fluoroimmunoassay) kit based on IMB (immunomagnetic beads). The kit includes a calibrator, immunomagnetic beads connected with CEA antibodies, europium labeled CEA antibodies, an assay buffer solution, a cleaning solution and an enhanced solution. Through double antibody sandwich immunoreaction, IMB-CEA-europium labeled-CEA monoclonal antibody complexes are formed, IMB which adsorb CEA and supernate are separated through magnetic seperation and washed, the enhanced solution is added, and the value is measured through a time-resolved instrument. Besides the TRFIA technology, the invention further has the advantages as follows: through IMB enrichment and full diffusion of IMB in the solution, the combination superficial area is enlarged, the reaction time is greatly shortened, and the detection sensitivity is improved. IMB and antibodies are directionally connected through chemical groups, so that the consumption of paired antibodies is greatly reduced and the detection precision is improved. The technology realizes automation easily, and overcomes the problem that the traditional micropore plate type TRFIA technology can only carry out detection after samples are accumulated to a certain number, thereby realizing real-time sample detection.

The invention belongs to the cancer detection technology, relating to a lung cancer marker detection immunochromatographic test paper and an application. The detection of a single tumour marker in the prior art can not meet the requirements of clinical early diagnosis and differential diagnosis. The invention realizes the early diagnosis of lung cancer by jointly detecting NSE and CEA in serum with a double antibody sandwich immunochromatography. The invention comprises the following preparation steps: preparing aurosol-neure NSE and aurosol-carcinoembryonic antigen CEA antibody compounds; preparing double antibody sandwich NSE and CEA detection test strips. The invention comprises the following steps in lung cancer detection: configurating series concentration NSE and CEA standard substances; preparing NSE and CEA mixed antigen solution with serum of normal people; inserting the sample pad ends of the test strips into the above concentration series standard substances respectively to observe the changes in colours of T and C lines on a NC film. The invention has the advantages of convenient detection operation, high sensitivity and precise result, and can determine lung cancer recurrence 4-12 weeks ahead.

The present invention relates to target medicine of nanometer magnetic powder and anti-CEA antibody for magentothermical therapy on colon cancer, stomach cancer, liver cancer, etc. The present invention features that nanometer magnetic powder and antibody in the weight ratio of 1 to 0.0001-0.20 are coupled via mixing in solution to prepare the nanometer target medicine. The target medicine has grain size one 5-1000 nm, nanometer magnetic powder with one or several antibodies coupled to the surface, and bioactivity. The target medicine is injection with medicine dispersed into nanometer grains, and is targeted and concentrated to the cancer focus. Under the action of the AC magnetic field of the magentothermical therapy instrument, the target medicine produces hysteresis heat effect of 10-7000 W/gFe to heat the cancer focus to 42-95 deg.c and kill cancer cell. The target medicine has biodegrading function and is used in the magentothermical treatment of cancer without toxic side effect.

The present invention concerns compositions and methods of use of a humanized Class III anti-CEA antibody, comprising the heavy and light amino acid sequences SEQ ID NO:1 and SEQ ID NO:2. The antibody is effective to treat CEACAM5-expressing tumors, either alone or in combination with one or more therapeutic agents. Drug conjugated Class III anti-CEA antibodies, such as SN-38 or P2PDox immunoconjugates, are particularly efficacious. Surprisingly, the antibody-drug conjugates (ADCs) exhibit high anti-cancer efficacy, while exhibiting low levels of systemic toxicity that are readily treated with standard amelioration techniques. Antibodies and/or immunoconjugates comprising the amino acid sequences SEQ ID NO:1 and SEQ ID NO:2 are surprisingly efficacious for therapy of solid tumors, even when the tumor has proven resistant to standard anti-cancer therapies.

The present invention provides molecules, preferably designed immunoglubulins, suitable for use as an anti-idiotype vaccine to CEA positive tumours. The molecules induce both an MHC class I and MHC class II mediated immune response to the CEA bearing tumour cells for an efficient and sustained host anti-tumour response. The present invention provides modified versions of anti-idiotype anti-CEA antibodies, preferably mouse antibody 708, with improved vaccination properties. The modifications are related to the introduction of sequences tracts deriving from e.g. CEA, CD55 antigen and CEA cancer-specific MHC epitopes into the variable regions of said antibody molecules.

The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.

The invention relates to a method for preparing an electrochemical luminescence sensor made of nano-composites. The method includes the three steps that Au-and-BSA nano-materials are prepared; luminol is crosslinked to the surfaces of the Au-and-BSA nano-materials through glutaraldehyde, carboxyl on the surfaces of the Au-and-BSA nano-materials is activated to be connected with CEA antibodies to obtain luminol-Au-and-BSA-anti-CEAs; a gold nano-layer is electrodeposited on the surface of a naked glassy carbon electrode serving as a working electrode with an electro-deposition method, the obtained luminol-Au-and-BSA-anti-CEAs are connected to the surface of the electrode, and the electrochemical luminescence immunosensor with the targeting effect on CEAs is obtained. The method is rapid, easy and convenient, and the constructed immunosensor has the advantages of being good in biocompatibility, high in specificity and sensitivity, wide in detection range and the like.

The invention relates to a magnetic immuno-chromatographic test paper strip for quantitatively detecting carcinoembryonic antigen in blood and a preparation method thereof. A coating film, a magnet particle pad combined with CEA antibodies, a sample pad and a water absorbing pad are sequentially and alternately stuck on a base plate in a staggering way at intervals of 2mm, and then the upper layer is covered by a transparent plastic sealing film to form a test paper strip. A CEA antibody detection line and a quality control line are pre-coated on the coating film. The invention introduces the magnetic immuno-chromatographic technology and the biotin-aviden system into the quantitative detection of CEA in blood, and has the advantages that the detection sensitivity is greatly improved, the accurate quantitative results can be given, the labor strength of the operators is reduced, and the clinicians can rapidly and accurately diagnose the illness of patients.

The present invention discloses an immunochromatographic test paper strip which includes a sample pad, a conjugate pad, a nitrocellulose membrane, testing lines, a quality control line, a water absorbent pad and a backing plate; the conjugate pad is loaded with two immunofluorescence probes using quantum dots as markers, and the quantum dots are respectively coupled with a NSE antibody and a CEA antibody to form anti-NSE immunofluorescence and anti-CEA immunofluorescence probes; and the number of the testing lines is two, one testing line includes the NSE antibody, and the other testing line includes the CEA antibody. The immunochromatographic test paper strip is simple and fast in detection, intuitive in test results, capable of qualitatively, quantitatively even semi-quantitatively detecting, and low in price, can simultaneously detect two or more tumor markers, and achieves multiple detection of the tumor markers by use of the quantum dot test paper strip for detection.

The invention belongs to a field of immunization analysis and diagnosis technology, and concretely relates to a visual multicolor detection kit for antigen-antibody reaction and a using method of kit. According to the invention, the kit comprises CEA antibodies labeled with grapheme modified by methyl red; NSE antibodies labeled with grapheme modified by phenolphthalein;Cyfra21-1 antibodies labeled with grapheme modified by thymolphthalein; a 96-well plate coated with a monoclonal antibody mixture containing CEA, NSE and Cyfra21-1 antibody; alkaline water whose pH value is 12.0; and a PBST buffersolution. The kit provided by the invention can be used for simultaneous multicolor detection of CEA, NSE and Cyfra21-1 antigen. The kit provided by the invention has the advantages of simple operation, high efficiency and low cost, and is convenient to be used in the places short of resource and less developed areas.

The invention provides an anti-CEA antibody. The anti-CEA antibody comprises a heavy chain variable region and a light chain variable region, wherein a complementary determining region of the heavy chain variable region comprises CDR-H1 with an amino acid sequence shown as SEQ ID No. 1, CDR-H2 with an amino acid sequence shown as SEQ ID No. 2 and CDR-H3 with an amino acid sequence shown as SEQ IDNo. 3; a complementation determining region of the light chain variable region comprises CDR-L1 with an amino acid sequence shown as SEQ ID No. 4, CDR-L2 with an amino acid sequence shown as SEQ ID No. 5 and CDR-L3 with an amino acid sequence shown as SEQ ID No. 6. The CEA scFv is screened by an inventor of the invention by utilizing a phage display technology, so that the CEA-resistant single-chain antibody with high affinity is obtained. An anti-CEA chimeric antigen receptor gene is introduced into T cells through a genetic engineering method to prepare CEA CAR-T, so that the CEA CAR-T cellsspecifically recognize digestive tract tumor cells expressing CEA and kill the digestive tract tumor cells, and the anti-tumor effect of the CEA CAR-T cells is achieved.